Follow
T-Cells
T-Cells: A type of white blood cell that plays an important role in the immune system. They are produced by the thymus gland and help the body fight off viruses, bacteria, and parasites.
OCT 02, 2025 | 8:00 AM
CAR-T Therapy continues to evolve rapidly, mRNA encoding CAR constructs directly to T cells in the bloodstream, potentially enabling CAR T cell production in the body without the need to iso...
OCT 01, 2025 | 7:30 AM
C.E. CREDITS
Non-small cell lung cancer (NSCLC) accounts for more deaths than colon, breast, and prostate cancers combined. Of patients with NSCLC, 20% initially present with stage I or II disease, for w...
SEP 17, 2025 | 8:00 AM
Ivonescimab is a that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor (VEGF), two key molecules in the tumour microenvironment. It's...
MAY 14, 2025 | 9:00 AM
While hundreds of different lipids have been identified in human blood, many of them remain functionally uncharacterized, including a class of lipids called long-chain acylcarnitines (LCACs)...
MAY 13, 2025 | 9:00 AM
Immune checkpoint blockade (ICB) targeting T cells has enhanced clinical outcomes in patients with renal and bladder cancers; however, response rates remain limited, particularly in cases of...
MAY 08, 2025 | 8:00 AM
The HIV-1 Nef accessory factor promotes viral replication and immune escape of HIV-infected cells, making it an attractive drug target. Our team previously identified small molecules that bi...
On Demand
C.E. CREDITS
Clinical effectiveness of immune therapies of solid tumors requires a) the induction or expansion of T cells able of recognizing multiple variants of cancer cells present in each cancer pati...
DEC 04, 2024 | 8:30 AM
Expression of co-inhibitory receptors or “checkpoint” molecules, such as CTLA-4 and PD-1, on effector T cells is a key mechanism for ensuring immune homeostasis. Dysregulated exp...
NOV 07, 2024 | 8:00 AM
High resolution surveys of the tumor microenvironment (TME) are needed to obtain a holistic portrait of the genetic, epigenetic, and cellular factors contributing to cancer progression. To t...
OCT 16, 2024 | 1:00 PM
C.E. CREDITS
T cell lymphocytes play a central role in the adaptive immune response. They are an essential tool of adoptive cell therapy for the treatment of chronic viral infections and malignant diseas...
OCT 03, 2024 | 10:00 AM
Advances in proteomics and mass spectrometry enable the study of limited cell populations such as performing mouse models. Low-protein load studies often requires two steps to perform differ...
On Demand
C.E. CREDITS
Engineered immune cell therapies offer the promise of more tailored interventions than traditional systemic checkpoint blockades, but so far remain ineffective across the majority of clinica...
SEP 12, 2024 | 8:00 AM
Neoantigens are among the newest promising targets for cancer treatment. Unlike tumor-associated antigens, neoantigens are produced only by tumor cells. These unique molecular markers are hi...
JUN 04, 2024 | 8:45 AM
Cancer immunotherapy approaches such as adoptive transfer of chimeric antigen receptor (CAR) T cells or tumor-infiltrating lymphocytes have yielded promising results in hematological maligna...
MAY 14, 2024 | 9:00 AM
C.E. CREDITS
Survival rates for patients with high grade serous carcinoma of the ovary (HGSC) have stagnated for the past fifty years. Despite the presence of tumor mutations and infiltration of immune c...
APR 30, 2024 | 1:00 PM
Chimeric antigen receptor (CAR) T-cell therapy shows significant potential in treating various human cancers. Unfortunately, researchers have faced difficulty in adapting this therapy to tar...
APR 30, 2024 | 10:30 AM
C.E. CREDITS
Despite the remarkable clinical efficacy of chimeric antigen receptor (CAR) T cells in hematological malignancies, only a subset of patients achieve a durable complete response. Furthermore,...
